Pulmonary vascular remodeling: A target for therapeutic intervention in pulmonary hypertension

Pharmacology and Therapeutics

Volumn 92, Issue 1, 2001, Pages 1-20

  Jeffery, Trina K ^a   Wanstall, Janet C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anti remodelling drugs; Pulmonary blood vessels; Pulmonary hypertension; Pulmonary vascular remodelling

Indexed keywords

3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMITOTIC AGENT; ATRASENTAN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYTOKINE; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELASTASE; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; ENZYME INHIBITOR; GROWTH FACTOR; HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROTEIN KINASE C; SERINE ELASTASE; SERINE ELASTASE INHIBITOR; SEROTONIN; SITAXSENTAN; TENASCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CALCIUM CELL LEVEL; CELL HYPERPLASIA; CELL TYPE; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; ENDOTHELIUM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HYPERTROPHY; HYPOXIA; IMAGE ANALYSIS; INTIMA; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG COMPLIANCE; LUNG VASCULAR RESISTANCE; NONHUMAN; PATHOPHYSIOLOGY; PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SHEAR STRESS;

EID: 0035676884     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(01)00157-7     Document Type: Review

References (218)

1. Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia
2. Hypoxia-induced release of peptide growth factors from neonatal porcine pulmonary artery smooth muscle cells
3. Role of nitric oxide in regulating neonatal porcine pulmonary artery smooth muscle cell proliferation
4. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension
5. Basic fibroblast growth factor alterations during development of monocrotaline-induced pulmonary hypertension in rats
6. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension
7. Hypoxic pulmonary vasoconstriction in chronically hypoxic rats
8. Alveolar hypoxia increases gene expression of extracellular matrix proteins and platelet-derived growth factor-B in lung parenchyma
9. Stretching increases calcium influx and efflux in cultured pulmonary arterial smooth muscle cells
10. ZD1611, an orally active endothelin-A receptor antagonist, prevents chronic hypoxia-induced pulmonary hypertension in the rat
11. 2+-channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle cells
12. A-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats
13. 1 is decreased in remodeling hypertensive bovine pulmonary arteries
14. Primary pulmonary hypertension and fenfluramine use
15. Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats
16. Endothelin-1 in pulmonary hypertension
17. Angiotensin II and monocrotaline-induced pulmonary hypertension: Effect of losartan (duP 753), a nonpeptide angiotensin type 1 receptor antagonist
18. Lung angiotensin receptor binding characteristics during the development of monocrotaline-induced pulmonary hypertension
19. Identification of stretch-responsive genes in pulmonary artery smooth muscle cells by a two arbitrary primer-based mRNA differential display approach
20. Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension
21. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
22. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodelling in Sprague-Dawley rats
23. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
24. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension
25. Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat
26. Effects of cilazapril, a novel angiotensin converting enzyme inhibitor, on the structure and function of pulmonary arteries of rats exposed to chronic hypoxia
27. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
28. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth
29. Hypoxia stimulates proliferation and interleukin-1 α production in human vascular smooth muscle cells
30. Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis
31. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor
32. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease
33. Difference between basal release of nitric oxide and response to acetylcholine in isolated lungs from patients with chronic obstructive lung disease
34. Chronic hypoxia induces exaggerated growth responses in pulmonary artery adventitial fibroblasts
35. Diverse effects of heparin on mitogen-activated protein kinase-dependent signal transduction in vascular smooth muscle cells
36. Characterization of fibroblast mitogens and chemoattractants produced by endothelial cells exposed to hypoxia
37. The role of endothelium in vascular remodeling
38. Insulin-like growth factor 1 and protein kinase C activation stimulate pulmonary artery smooth muscle cell proliferation through separate but synergistic pathways
39. Protein kinase C activation allows pulmonary artery smooth muscle cells to proliferate to hypoxia
40. Heterogeneity in the proliferative response of bovine pulmonary artery smooth muscle cells to mitogens and hypoxia: Importance of protein kinase C
41. ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat
42. Pulmonary arteries and veins in experimental hypoxia
43. Urinary nitrite and nitrate concentrations in patients with idiopathic persistent pulmonary hypertension of the newborn and effect of extracorporeal membrane oxygenation
44. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats
45. Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats
46. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin
47. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene
48. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy
49. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat
50. Mechanical properties and reactivity of vessels in isolated perfused lungs of chronically hypoxic rats
51. Endothelial cell responses to hypoxic stress
52. A new role for an old molecule: Serotonin as a mitogen
53. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats
54. Heparin attenuates pulmonary vascular thickening in chronically hypoxic neonatal calves
55. Neither anticoagulant nor nonanticoagulant heparin affects monocrotaline lung injury
56. Quantitative changes in rat pulmonary vasculature in chronic hypoxia - Relation to haemodynamic changes
57. The haemodynamic consequences of adaptive structural changes of the resistance vessels in hypertension
58. Background of increased flow resistance and vascular reactivity in spontaneously hypertensive rats
59. Smooth muscle cells isolated from discrete compartments of the mature vascular media exhibit unique phenotypes and distinct growth capabilities
60. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension
61. Nitric oxide and endothelin-1 in pulmonary hypertension
62. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
63. Polyamines and epidermal growth factor in monocrotaline-induced pulmonary hypertension
64. The pulmonary hypertensive fawn-hooded rat has a normal serotonin transporter coding sequence
65. Impairment of hypoxic pulmonary artery remodeling by heparin in mice
66. E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats
67. Ultrastructure of plexogenic arteriopathy
68. Effect of heparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodelling in the guinea pig
69. Endothelin 1: Mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells
70. Mechanism of action of the inhibitory effect of nifedipine on the growth of cultured aortic cells from spontaneously hypertensive and normotensive rats
71. Primary pulmonary hypertension in a patient with familial storage pool disease: Role of serotonin
72. Increased plasma serotonin in primary pulmonary hypertension
73. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats
74. Arterial changes in Crotalaria spectabilis-induced pulmonary hypertension in rats
75. New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension
76. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats
77. The effect of heparin on the haemodynamic and structural response in the rat to acute and chronic hypoxia
78. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension
79. SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats
80. The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats
81. Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus
82. Increased lung preproET-1 and decreased ETB-receptor gene expression in fetal pulmonary hypertension
83. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells
84. Perindopril, an angiotensin converting enzyme inhibitor, in pulmonary hypertensive rats: Comparative effects on pulmonary vascular structure and function
85. Pulmonary vascular remodelling in hypoxic rats: Effects of amlodipine, alone and with perindopril
86. Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia
87. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation
88. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease
89. Vascular remodeling in clinical and experimental pulmonary hypertensions
90. Nitric oxide impacts endothelin-1 gene expression in intrapulmonary arteries of chronically hypoxic rats
91. Inhibition of PDGF-mediated proliferation of vascular smooth muscle cells by calcium antagonists
92. Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension
93. Failure to show decrease in small pulmonary blood vessels in rats with experimental pulmonary hypertension
94. Pulmonary artery pressure in rats with hereditary platelet function defect
95. Reduction of chronic hypoxic pulmonary hypertension in the rat by beta-aminopropionitrile
96. Reduction of chronic hypoxic pulmonary hypertension in the rat by an inhibitor of collagen production
97. Heparin-like molecules inhibit pulmonary vascular pericyte proliferation in vitro
98. Endothelin mediates pulmonary vascular remodeling in a canine model of chronic embolic pulmonary hypertension
99. 1 and extracellular matrix gene expressions by cilazapril and nifedipine in hypertensive rats
100. Both membrane stretch and fatty acids directly activate large conductance Ca(2+)-activated K+ channels in vascular smooth muscle cells
101. Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats
102. Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells
103. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats
104. Effect of mechanical forces on growth and matrix protein synthesis in the in vitro pulmonary artery. Analysis of the role of individual cell types
105. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia
106. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats
107. Stretch increases inositol trisphosphate and inositol tetrakisphosphate in cultured pulmonary vascular smooth muscle cells
108. Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture
109. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture
110. Inhibitory effect of heparin on serotonin-induced hyperplasia and hypertrophy of smooth muscle cells
111. Effects of chronic converting enzyme inhibition on the structure and function of large arteries in the rat
112. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia
113. Interleukin 1: A mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids
114. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: Changes in pulmonary hypertension
115. Effect of hypoxia on prostacyclin production in cultured pulmonary artery endothelium
116. Endothelin induced collagen remodeling in experimental pulmonary hypertension
117. Continuous low-dose NO inhalation does not prevent monocrotaline- induced pulmonary hypertension in rats
118. Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity
119. Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension
120. Pulmonary hypertension - Advances in medical and surgical interventions
121. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
122. Hypoxia-induced structural changes in the media and adventitia of the rat hilar pulmonary artery and their regression
123. Endothelial and subendothelial changes in rat hilar pulmonary artery during recovery from hypoxia
124. Nitrendipine attenuates the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia in rats
125. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats
126. Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMP-mediated suppression of ERK phosphorylation and AML1B nuclear partitioning
127. Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist
128. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension
129. Monocrotaline-induced pulmonary fibrosis in rats: Amelioration by captopril and penicillamine
130. Monocrotaline-induced cardiopulmonary injury in rats: Modification by the nonthiol ACE inhibitors CGS13945 and CGS16617
131. Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP
132. Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension
133. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension
134. 1 receptors
135. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension
136. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats
137. Expression of endothelin-1 in rats developing hypobaric hypoxia-induced pulmonary hypertension
138. LU135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction
139. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling
140. Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation
141. PAF receptor blockade inhibits lung vascular changes in the rat monocrotaline model
142. PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats
143. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension
144. Estradiol improves pulmonary hemodynamics and vascular remodeling in perinatal pulmonary hypertension
145. Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts
146. Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension
147. Insulin-like growth factor I and pulmonary hypertension induced by continuous air embolization in sheep
148. Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture
149. Collagen and elastin metabolism in hypertensive pulmonary arteries of rats
150. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats
151. eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia
152. Early pulmonary vascular changes in congenital heart disease studied in biopsy tissue
153. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy
154. The case for treatment of selected patients with primary pulmonary hypertension
155. Functional basis for the structure of the pulmonary arterial tree
156. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat
157. Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups
158. Platelet-derived growth factor and angiotensin II cause increases in cytosolic free calcium by different mechanisms in vascular smooth muscle cells
159. Chronic inhaled nitric oxide: Effects on pulmonary vascular endothelial function and pathology in rats
160. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension
161. Immediate-early gene expression in response to hypertrophic and proliferative stimuli in pulmonary arterial smooth muscle cells
162. Pulmonary hypertensive diseases
163. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat
164. Angiotensin converting enzyme expression in primary pulmonary hypertension
165. A receptor antagonist (CI-1020) in rats with established hypoxic pulmonary hypertension
166. Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension
167. Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats
168. Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists
169. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension
170. Cellular and molecular mechanisms of pulmonary vascular remodeling
171. Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4300m
172. Amlodipine and vascular hypertrophy
173. Amlodipine inhibition of serum-, thrombin- or fibroblast growth factor-induced vascular smooth muscle cell proliferation
174. Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodeling
175. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
176. Pathology of adult pulmonary hypertension
177. Amlodipine inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension
178. A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension
179. Endothelin converting enzyme inhibitor protects against development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension
180. The effect of nitric oxide on fetal pulmonary artery smooth muscle growth
181. Inhibition of hypoxic pulmonary hypertension by heparins of differing in vitro antiproliferative potency
182. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor
183. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist
184. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease
185. Pressure-induced connective tissue synthesis in pulmonary artery segments is dependent on intact endothelium
186. Excess collagen in hypertensive pulmonary arteries decreases vascular distensibility
187. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension
188. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide
189. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension
190. Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension
191. Pathogenesis of pulmonary hypertension in the rat model
192. Chronic hypoxia-induced cardiopulmonary changes in three rat strains: Inhibition by the endothelin receptor antagonist SB 217242
193. Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension
194. The role of endothelial cells in the proliferative response of cultured pulmonary vascular smooth muscle cells to reduced oxygen tension
195. Reduced oxygen tension induces pulmonary endothelium to release a pulmonary smooth muscle cell mitogen(s)
196. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension
197. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline
198. Pathophysiology of primary pulmonary hypertension: From physiology to molecular mechanisms
199. Effect of alveolar pressure on pulmonary artery pressure in chronically hypoxic rats
200. Effects of tetrandrine on growth factor-induced DNA synthesis and proliferative response of rat pulmonary artery smooth muscle cells
201. Recognition and management of pulmonary hypertension
202. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells
203. A pathophysiological study of 10 cases of hypoxic Cor Pulmonale
204. Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia
205. Hypoxia selectively induces proliferation in a specific subpopulation of smooth muscle cells in the bovine neonatal pulmonary arterial media
206. The prostacyclin-mimetic cicaprost inhibits endogenous endothelin-1 release from human pulmonary artery smooth muscle cells
207. Pulmonary artery smooth muscle cells from chronically hypoxic neonatal calves retain fetal-like and acquire new growth properties
208. Endothelin-1 activates MAP kinases and c-Jun in pulmonary artery smooth muscle
209. Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension
210. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects; evidence for increased production of endothelin in pulmonary circulation
211. Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline
212. Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I-converting enzyme in the rat
213. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells
214. Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats
215. Pulmonary vascular remodeling
216. Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung
217. Alteration of the pulsatile load in the high-altitude calf model of pulmonary hypertension